Skip to main content

                                                                                New Content Item

What's new?

We are delighted to announce that Cancer & Metabolism's new 2 Year Impact Factor is 5.9, with a 5 Year Impact Factor of 6.3 

Thank you to our Editors-in-Chief Dr. Michael Pollak and Dr. Matthew G. Vander Heiden for their hard work and to all those who support this journal.

Aims and scope

Cancer & Metabolism welcomes studies on all aspects of the relationship between cancer and metabolism, including:

  • Molecular biology and genetics of cancer metabolism
  • Whole-body metabolism, including diabetes and obesity, in relation to cancer
  • Metabolomics in relation to cancer;
  • Metabolism-based imaging
  • Preclinical and clinical studies of metabolism-related cancer therapies.

Learn more here


Colorectal Cancer Awareness Month

In recognition of Colorectal Cancer Awareness Month this March, we have selected a collection of articles on colorectal cancer from across our open access portfolio. Together, these articles contribute to the evolving landscape of colorectal cancer research and the fight against this prevalent and impactful disease.
© Mopic /

Editorial Board

Dr. Michael Pollak, co-Editor-in-Chief

Dr. Pollak is an internationally recognized expert in cancer endocrinology at the Lady Davis Institute for Medical Research of McGill University and a clinical oncologist at the Jewish General Hospital, Quebec, Canada.

"Cancer & Metabolism will provide a forum for rapid dissemination of research findings concerning metabolic factors that influence cancer risk and cancer pathophysiology, and cancer treatment. The scope of the Journal will allow for an interdisciplinary readership including cancer biologists, endocrinologists, oncologists, clinical trialists and population scientists."

New Content ItemDr. Matthew G. Vander Heiden, co-Editor-in-Chief

Dr. Vander Heiden is Associate Director at the Koch Institute for Integrative Cancer Research at MIT. Extensively published in over 140 peer reviewed articles and book chapters, his research interests focus on the metabolic processes of cancer cells, including how glucose metabolism affects tumor growth and how these studies may lead to new developments in targeted cancer therapy. A renowned innovative researcher in his field, Dr. Vander Heiden received the 2017 Philip A. Sharp Innovation in Collaboration Award from Stand Up to Cancer (SU2C).

New Content ItemDr. Costas Lyssiotis, Deputy Editor

Dr. Lyssiotis is the Maisel Research Professor of Oncology and an Associate Professor of Physiology and Medicine at the University of Michigan. The Lyssiotis research group studies the biochemical pathways and metabolic requirements that enable tumor survival and growth. This work spans the areas of cancer metabolism, the tumor microenvironment, and immunometabolism using and developing protocols in mass spectrometry-based metabolomics. Dr. Lyssiotis has published >150 peer reviewed research papers, and as a reflection of the impact of his work, he has been recognized as a highly cited researcher (top 1% across sciences) by Web of Science.

Associate Editors:

Kivanc Birsoy, 
The Rockefeller University, USA
Kevin Brindle, University of Cambridge, UK
Navdeep Chandel, Northwestern University, USA
Maralice Conacci Sorrell, University of Texas Southwestern Medical Center, USA
Lydia Finley, Memorial Sloan Kettering Cancer Center, USA
Christian Frezza, University Hospital Cologne, Germany
Richard G. Kibbey, Yale University School of Medicine, USA
Mioara Larion, National Cancer Institute, Center for Cancer Research, National Institutes of Health, USA
Jason Locasale, Duke University School of Medicine, USA
Christian Metallo, Salk Institute for Biological Studies, USA
Rachel Perry, Yale University School of Medicine, USA
Julie St-Pierre, University of Ottawa, Canada

Editorial Board Members:

Abass AlaviUniversity of Pennsylvania School of Medicine, USA
Lewis Cantley, Weill Cornell Medical College, USA
Peter CarmelietVesalius Research Center, Belgium
Gina DeNicola, Moffitt Cancer Center, USA


Andrew LaneMarkey Cancer Center, USA
Sophia Lunt, Michigan State University, USA
Christian Metallo, University of California, San Diego Department of Bioengineering, USA
Gordon Mills, University of Texas M. D. Anderson Cancer Center, USA
Michael E Pacold, New York University Langone Health, USA
Thales Pappagiannokopoulos, NYU Grossman School of Medicine, USA
Jacques PouyssegurInstitute of Research on Cancer and Aging, France
Joshua Rabinowitz, Princeton University, USA
Peter RatcliffeNuffield Department of Clinical Medicine, UK
Jeffrey Rathmell, Duke University, USA
Jared RutterUniversity of Utah School of Medicine, USA
Gregg Semenza, Johns Hopkins University School of Medicine, USA
Celeste Simon, University of Pennsylvania School of Medicine, USA
Bert Vogelstein, Johns Hopkins University School of Medicine, USA
Karen Vousden, Beatson Institute for Cancer Research, UK
Eileen White, The Cancer Institute of New Jersey, USA
Robert Gatenby, Moffitt Cancer Center, USA
Kun-Liang GuanUniversity of  California, USA

Chi Van Dang, Editor Emeritus

Chi Dang is a professor, physician-researcher, renowned cancer biologist and hematologist-oncologist, who serves as director of the Abramson Cancer Center at the University of Pennsylvania.

"After several decades of profound advances in our understanding of the genetics and molecular biology of cancer, it has become self-evident that metabolism and bioenergetics are regulated by cancer genes and are intimately linked to the growth and survival of cancer cells. The obesity pandemic connected to increased cancer risk further underscore the importance of a richer understanding of cancer and organismal metabolism. In this regard, Cancer & Metabolism is launched uniquely to fulfill the needs of a burgeoning field which is at the crossroads of many scientific disciplines."

World Cancer Day 2021

New Content Item

The Editors of Cancer & Metabolism are delighted to highlight the following paper to mark the World Cancer Day:

Metabolic plasticity of IDH1-mutant glioma cell lines is responsible for low sensitivity to glutaminase inhibition

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 6.0
    5-year Journal Impact Factor: 5.4
    Source Normalized Impact per Paper (SNIP): N/A
    SCImago Journal Rank (SJR): N/A

    Speed 2023
    Submission to first editorial decision (median days): 15
    Submission to acceptance (median days): 149

    Usage 2023
    Downloads: 398,435
    Altmetric mentions: 311

Springer Nature Oncology Portfolio

Discover the range of academic oncology titles at Springer Nature here.